Selank

Also known as: TP-7, N-Acetyl Selank

**Mechanism of Action** Selank (TP-7) is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, modified with a C-terminal Pro-Gly-Pro sequence. Its primary mechanisms involve modulation of the GABAergic system, particularly enhancing GABA-A receptor sensitivity, and stabilization of endogenous enkephalins by inhibiting their enzymatic degradation. This dual action reduces anxiety-like behaviors without sedation and supports cognitive processes such as learning and memory. Additionally, Selank influences serotonin and dopamine turnover in limbic structures, contributing to its anxiolytic and nootropic profile. **Key Research Findings** Clinical trials and preclinical studies (68 PubMed-indexed references) demonstrate Selank’s efficacy in generalized anxiety disorder (GAD) and asthenic conditions, with rapid onset and minimal side effects compared to benzodiazepines. It improves attention, working memory, and stress resilience in healthy volunteers and patients with cognitive decline. Animal models show neuroprotective effects against oxidative stress and inflammation, with modulation of cytokine levels (e.g., IL-6, TNF-α). Selank also exhibits immunomodulatory properties, enhancing T-cell activity and antibody production, though its clinical significance in immune disorders remains under investigation. **Clinical Relevance** Selank is approved in Russia for anxiety disorders and asthenia, with ongoing trials exploring its use in cognitive impairment, post-traumatic stress disorder (PTSD), and chronic fatigue syndrome. Its favorable safety profile—lacking sedation, dependence, or withdrawal—positions it as a potential alternative to conventional anxiolytics. However, regulatory status outside Russia remains limited, and further large-scale trials are needed to confirm efficacy in broader populations. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides